Cargando…

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial

The Hippo pathway effector YAP is dysregulated in malignant pleural mesothelioma (MPM). YAP's target genes include the secreted growth factor amphiregulin (AREG), which is overexpressed in a wide range of epithelial cancers and plays an elusive role in MPM. We assayed the expression of YAP and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maille, Elodie, Levallet, Jérôme, Dubois, Fatéméh, Antoine, Martine, Danel, Claire, Creveuil, Christian, Mazieres, Julien, Margery, Jacques, Greillier, Laurent, Gounant, Valérie, Moro‐Sibilot, Denis, Molinier, Olivier, Léna, Hervé, Monnet, Isabelle, Bergot, Emmanuel, Langlais, Alexandra, Morin, Franck, Scherpereel, Arnaud, Zalcman, Gérard, Levallet, Guénaëlle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Molecular Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545369/ https://www.ncbi.nlm.nih.gov/pubmed/35262190 http://dx.doi.org/10.1002/ijc.33997

Ejemplares similares

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial
por: Levallet, Guénaëlle, et al.
Publicado: (2016)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
por: Dubois, Fatéméh, et al.
Publicado: (2019)

RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis—an updated review
por: Dubois, Fatéméh, et al.
Publicado: (2019)

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
por: Bergot, Emmanuel, et al.
Publicado: (2013)

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells
por: Keller, Maureen, et al.
Publicado: (2019)

The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas
por: Levallet, Guénaëlle, et al.
Publicado: (2022)

A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control
por: Dubois, Fatéméh, et al.
Publicado: (2018)

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
por: Molinier, O., et al.
Publicado: (2021)

Centrosome, the Newly Identified Passenger through Tunneling Nanotubes, Increases Binucleation and Proliferation Marker in Receiving Cells
por: Dubois, Fatéméh, et al.
Publicado: (2021)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

Investigating Tunneling Nanotubes in Cancer Cells: Guidelines for Structural and Functional Studies through Cell Imaging
por: Dubois, Fatéméh, et al.
Publicado: (2020)

A Biphasic and Brain-Region Selective Down-Regulation of Cyclic Adenosine Monophosphate Concentrations Supports Object Recognition in the Rat
por: Hotte, Maïte, et al.
Publicado: (2012)

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
por: Couraud, S., et al.
Publicado: (2013)

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
por: Girard, N., et al.
Publicado: (2022)

Contribution of the Idylla(TM) System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations
por: Petiteau, Constance, et al.
Publicado: (2021)

Optimization of Advanced Live-Cell Imaging through Red/Near-Infrared Dye Labeling and Fluorescence Lifetime-Based Strategies
por: Bénard, Magalie, et al.
Publicado: (2021)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers
por: Riffet, Marc, et al.
Publicado: (2021)

New Histoprognostic Factors to Consider for the Staging of Colon Cancers: Tumor Deposits, Invasive Tumor Infiltration and High-Grade Budding
por: Riffet, Marc, et al.
Publicado: (2023)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
por: Croix, Manuel, et al.
Publicado: (2023)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
por: Bennouna, Jaafar, et al.
Publicado: (2018)

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy
por: Corroyer-Dulmont, Aurélien, et al.
Publicado: (2021)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
por: Pluvy, Johan, et al.
Publicado: (2019)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Amphiregulin Regulates Melanocytic Senescence
por: Pommer, Michaela, et al.
Publicado: (2021)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
por: Girard, N., et al.
Publicado: (2020)

Evaluating the adoption of cybersecurity and its influence on organizational performance
por: Hasani, Tahereh, et al.
Publicado: (2023)

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial
por: Quillien, Véronique, et al.
Publicado: (2016)

Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon
Publicado: (1992)

Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study
por: Lutringer-Magnin, Delphine, et al.
Publicado: (2012)

Expression of Amphiregulin in Enchondromas and Central Chondrosarcomas
por: Losada, Daniele Moraes, et al.
Publicado: (2021)

Stress-Induced Neuroprotective Effects of Epiregulin and Amphiregulin
por: Zhan, Libin, et al.
Publicado: (2015)

Blood and Salivary Amphiregulin Levels as Biomarkers for Asthma
por: Hachim, Mahmood Yaseen, et al.
Publicado: (2020)

Erratum for: Expression of Amphiregulin in Enchondromas and Central Chondrosarcomas
Publicado: (2021)

Hypofractionated carbon‐ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study
por: Saitoh, Jun‐ichi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bvh85o7ps5msatb7jl05fdv84b